CN102177177A - 包含结合于EBV(Epstein-Barr病毒)潜在性膜蛋白-1(LMP1)胞内域的抗体的药物组合物 - Google Patents

包含结合于EBV(Epstein-Barr病毒)潜在性膜蛋白-1(LMP1)胞内域的抗体的药物组合物 Download PDF

Info

Publication number
CN102177177A
CN102177177A CN2009801399618A CN200980139961A CN102177177A CN 102177177 A CN102177177 A CN 102177177A CN 2009801399618 A CN2009801399618 A CN 2009801399618A CN 200980139961 A CN200980139961 A CN 200980139961A CN 102177177 A CN102177177 A CN 102177177A
Authority
CN
China
Prior art keywords
lmp1
antibody
ebv
epstein
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801399618A
Other languages
English (en)
Chinese (zh)
Inventor
大冈忠正
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ooka Tadamasa
Original Assignee
NATIONAL CENTER FOR SCIENTIFIC RESEARCH
Universite Claude Bernard Lyon 1
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NATIONAL CENTER FOR SCIENTIFIC RESEARCH, Universite Claude Bernard Lyon 1 filed Critical NATIONAL CENTER FOR SCIENTIFIC RESEARCH
Publication of CN102177177A publication Critical patent/CN102177177A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN2009801399618A 2008-08-08 2009-08-07 包含结合于EBV(Epstein-Barr病毒)潜在性膜蛋白-1(LMP1)胞内域的抗体的药物组合物 Pending CN102177177A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08162083 2008-08-08
EP08162083.3 2008-08-08
PCT/EP2009/060277 WO2010015705A1 (en) 2008-08-08 2009-08-07 Pharmaceutical compositions comprising antibodies binding to the intracellular domain of ebv (epstein-barr virus) latent membrane protein-1 (lmp1)

Publications (1)

Publication Number Publication Date
CN102177177A true CN102177177A (zh) 2011-09-07

Family

ID=40210594

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801399618A Pending CN102177177A (zh) 2008-08-08 2009-08-07 包含结合于EBV(Epstein-Barr病毒)潜在性膜蛋白-1(LMP1)胞内域的抗体的药物组合物

Country Status (5)

Country Link
US (1) US20120107319A1 (enExample)
EP (1) EP2331572A1 (enExample)
JP (1) JP2011530277A (enExample)
CN (1) CN102177177A (enExample)
WO (1) WO2010015705A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103145849A (zh) * 2013-02-18 2013-06-12 冯振卿 嵌合抗原受体及其用途
CN111647564A (zh) * 2020-05-18 2020-09-11 李欣 抗eb病毒lmp1的单克隆抗体及其细胞株和应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012072516A1 (en) 2010-11-29 2012-06-07 Centre National De La Recherche Scientifique (Cnrs) Barf1 a diagnostic and prognostic marker for epstein-barr virus (ebv)-associated lymphoma
AU2017306301B2 (en) 2016-08-02 2023-12-07 Dana-Farber Cancer Institute, Inc. LMP1-expressing cells and methods of use thereof
MX2024007528A (es) 2021-12-23 2024-08-30 Sana Biotechnology Inc Linfocitos t del receptor de antígeno quimérico (car) para el tratamiento de enfermedades autoinmunitarias y métodos asociados.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003048337A2 (en) * 2001-12-04 2003-06-12 Dana-Farber Cancer Institute, Inc. Antibody to latent membrane proteins and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1229043A1 (en) * 2001-01-30 2002-08-07 Cyto-Barr B.V. Peptides derived from Epstein Barr virus (EBV) proteins LMP1, LMP2 and BARF1 antibody reagents reactive therewith

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003048337A2 (en) * 2001-12-04 2003-06-12 Dana-Farber Cancer Institute, Inc. Antibody to latent membrane proteins and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHIH-YEU FANG: "Construction and characterization of monoclonal antibodiesspecific to Epstein–Barr virus latent membrane protein 1", 《JOURNAL OF IMMUNOLOGICAL METHODS 》 *
GILLIGAN,K.: "GenBank: AAA66330.1，latent membrane protein [Human herpesvirus 4]", 《GENBANK》 *
KARIM HOUALI: "A New Diagnostic Marker for Secreted Epstein-Barr Virus-Encoded LMP1 and BARF1 Oncoproteins in the Serum andSaliva of Patients with Nasopharyngeal Carcinoma", 《CLIN CANCER RES》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103145849A (zh) * 2013-02-18 2013-06-12 冯振卿 嵌合抗原受体及其用途
CN103145849B (zh) * 2013-02-18 2014-06-11 冯振卿 嵌合抗原受体及其用途
CN111647564A (zh) * 2020-05-18 2020-09-11 李欣 抗eb病毒lmp1的单克隆抗体及其细胞株和应用

Also Published As

Publication number Publication date
EP2331572A1 (en) 2011-06-15
JP2011530277A (ja) 2011-12-22
WO2010015705A1 (en) 2010-02-11
US20120107319A1 (en) 2012-05-03

Similar Documents

Publication Publication Date Title
JP6703037B2 (ja) ヒトサイトメガロウイルス中和抗体およびその使用
JP7282401B2 (ja) 癌治療のための抗ｆａｍ１９ａ５抗体の用途
CN106132992B (zh) 针对muc1-c/胞外结构域(muc1-c/ecd)的抗体
TWI681972B (zh) 抗免疫原性醣肽之抗體，包含彼等之組合物及其用途
ES2929614T3 (es) Anticuerpos anti-MUC16 y usos de los mismos
CN103450359B (zh) 抗gdf-8的拮抗剂抗体以及在als和其他gdf-8-相关病症治疗中的用途
US11730813B2 (en) Broadly neutralizing antibodies directed against the rabies virus glycoprotein and uses thereof
EP2308895A1 (en) Anti-HSV antibody
CN109081868B (zh) 靶向寨卡病毒包膜蛋白保守表位的单克隆抗体及其应用
CN114867738B (zh) 肿瘤靶向蛋白或其片段、与其结合的抗体及其用途
US20250171547A1 (en) Epha3 directed car-t cells for treatment of tumors
WO2020047345A1 (en) Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
CN102177177A (zh) 包含结合于EBV(Epstein-Barr病毒)潜在性膜蛋白-1(LMP1)胞内域的抗体的药物组合物
TWI454279B (zh) 抗單純皰疹病毒抗體及其使用方法
JP2022536913A (ja) Ｐｄ－１に対する抗体およびその使用方法
US20140037623A1 (en) Pharmaceutical Compositions Comprising Antibodies Binding To EBV (Ebstein-Barr Virus) Protein BARF1
Tu et al. Virus-like particle vaccine displaying an external, membrane adjacent MUC16 epitope elicits ovarian cancer-reactive antibodies
TW202327664A (zh) 用於減少膜醣蛋白醣基化之抗體-藥物共軛物
WO2022068894A1 (zh) 同时靶向pd-l1和vegf的双功能分子及其医药用途
US20200055924A1 (en) Epstein-barr virus antibodies and uses thereof
KR20240072932A (ko) B7-h3에 특이적으로 결합하는 항체
JP2022536370A (ja) Ｐｄ－１に対する抗体およびその使用方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: OOKA TADAMASA

Free format text: FORMER OWNER: CENTRO NACIONAL DE INVESTIGACIONES CIENTIFICAS

Effective date: 20140225

Free format text: FORMER OWNER: CLAUDE BERNARD UNIVERSITY LYON 1

Effective date: 20140225

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20140225

Address after: lyon

Applicant after: Ooka Tadamasa

Address before: France

Applicant before: National Center for scientific research

Applicant before: Ucbl Universite Claude Bernard De Lyon 1

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110907